People who use illicit drugs (PWUD) face increased exposure to the criminal justice system and disproportionate burdens of HIV infection. This article investigated the effects of incarceration on HIV cascade of care-related measures in a setting with a community-wide seek, test, treat, and retain (STTR) initiative. Using a multivariable logistic regression analysis of 935 HIV-positive PWUD between 2005 and 2017, this article showed a negative relationship between periods of incarceration and two measures of engagement in clinical care for HIV among PWUD: recent dispensation of antiretroviral therapy and suppression of HIV viral load. These findings suggest the benefits of STTR-based efforts are limited by exposure to the criminal justice system and highlight the need for additional supports for PWUD with HIV exposed to the criminal justice system.
Get full access to this article
View all access options for this article.
References
1.
AndrewsD. A., BontaJ., & WormithJ. S. (2006). The recent past and near future of risk and/or need assessment. Crime & Delinquency, 52(1), 7–27. https://doi.org/10.1177/0011128705281756
2.
AndrewsD. A., ZingerI., HogeR. D., BontaJ., GendreauP., & CullenF. T. (1990). Does correctional treatment work? A clinically relevant and psychologically informed meta-analysis. Criminology, 28(3), 369–404. https://doi.org/10.1111/j.1745-9125.1990.tb01330.x
3.
BaillargeonJ., GiordanoT. P., RichJ. D., WuZ. H., WellsK., PollockB. H., & PaarD. P. (2009). Accessing antiretroviral therapy following release from prison. JAMA, 301(8), 848–857. https://doi.org/10.1001/jama.2009.202
CulbertG. J., WaluyoA., WangM., PutriT. A., BazaziA. R., & AlticeF. L. (2019). Adherence to antiretroviral therapy among incarcerated persons with HIV: Associations with methadone and perceived safety. AIDS and Behavior, 23(8), 2048–2058. https://doi.org/10.1007/s10461-018-2344-6
DhaliwalG. K., PorporinoF., & RossR. R. (1994). Assessment of criminogenic factors, program assignment, and recidivism. Criminal Justice and Behavior, 21(4), 454–467. https://doi.org/10.1177/0093854894021004005
8.
DolanK. A., ShearerJ., WhiteB., ZhouJ., KaldorJ., & WodakA. D. (2005). Four-year follow-up of imprisoned male heroin users and methadone treatment: Mortality, re-incarceration and hepatitis C infection. Addiction, 100(6), 820–828. https://doi.org/10.1111/j.1360-0443.2005.01050.x
HedrichD., AlvesP., FarrellM., StöverH., MøllerL., & MayetS. (2012). The effectiveness of opioid maintenance treatment in prison settings: A systematic review. Addiction, 107(3), 501–517. https://doi.org/10.1111/j.1360-0443.2011.03676.x
11.
HIV prevalence in prison is 15 times greater than in the community as a whole. (2010). HIV/AIDS Policy & Law Review, 15(1), 5–6.
12.
IrohP. A., MayoH., & NijhawanA. E. (2015). The HIV care cascade before, during, and after incarceration: A systematic review and data synthesis. American Journal of Public Health, 105(7), e5–e16. https://doi.org/10.2105/AJPH.2015.302635
13.
JosephB., WoodE., HayashiK., KerrT., BarriosR., ParasharS., RichardsonL., DobrerS., GuillemiS., MontanerJ., & MilloyM-J., (2016). Factors associated with initiation of antiretroviral therapy among HIV-positive people who use injection drugs in a Canadian setting. AIDS, 30(6), 925–932. https://doi.org/10.1097/QAD.0000000000000989
14.
JürgensR., NowakM., & DayM. (2011). HIV and incarceration: Prisons and detention. Journal of the International AIDS Society, 14, 26. https://doi.org/10.1186/1758-2652-14-26
15.
KerrT., MarshallB. D., MilloyM-J., ZhangR., GuillemiS., MontanerJ. S., & WoodE. (2012). Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users. Drug and Alcohol Dependence, 124(1–2), 108–112. https://doi.org/10.1016/j.drugalcdep.2011.12.019
16.
KoehnJ. D., BachP., HayashiK., NguyenP., KerrT., MilloyM-J., RiebL., & WoodE. (2015). Impact of incarceration on rates of methadone use in a community recruited cohort of injection drug users. Addictive Behaviors, 46, 1–4. https://doi.org/10.1016/j.addbeh.2015.01.038
17.
LoeligerK. B., AlticeF. L., DesaiM. M., CiarleglioM. M., GallagherC., & MeyerJ. P. (2018). Predictors of linkage to HIV care and viral suppression after release from jails and prisons: A retrospective cohort study. Lancet HIV, 5(2), e96–e106. https://doi.org/10.1016/S2352-3018(17)30209-6
MaruD. S., BruceR. D., WaltonM., MezgerJ. A., SpringerS. A., ShieldD., & AlticeF. L. (2008). Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy. AIDS and Behavior, 12(2), 284–293. https://doi.org/10.1007/s10461-007-9336-2
20.
MilloyM-J., KerrT., BuxtonJ., RhodesT., GuillemiS., HoggR., MontanerJ., & WoodE. (2011). Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. Journal of Infectious Diseases, 203(9), 1215–1221. https://doi.org/10.1093/infdis/jir032
21.
MilloyM-J., KerrT., BuxtonJ., RhodesT., KrusiA., GuillemiS., HoggR., MontanerJ., & WoodE. (2012). Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 59(4), 393–399. https://doi.org/10.1097/QAI.0b013e3182433288
22.
MilloyM-J., KerrT., SaltersK., SamjiH., GuillemiS., MontanerJ., & WoodE. (2013). Incarceration is associated with used syringe lending among active injection drug users with detectable plasma HIV-1 RNA: A longitudinal analysis. BMC Infectious Diseases, 13, 565. https://doi.org/10.1186/1471-2334-13-565
23.
MilloyM-J., KingA., KerrT., AdamsE., SamjiH., GuillemiS., WoodE., & MontanerJ. (2016). Improvements in HIV treatment outcomes among indigenous and non-indigenous people who use illicit drugs in a Canadian setting. Journal of the International AIDS Society, 19(1), 20617. https://doi.org/10.7448/IAS.19.1.20617
24.
MilloyM-J., MontanerJ. S., & WoodE. (2014). Incarceration of people living with HIV/AIDS: Implications for treatment-as-prevention. Current HIV/AIDS Reports, 11(3), 308–316. https://doi.org/10.1007/s11904-014-0214-z
25.
MilloyM-J., WoodE., KerrT., HoggB., GuillemiS., HarriganP. R., & MontanerJ. (2016). Increased prevalence of controlled viremia and decreased rates of HIV drug resistance among HIV-positive people who use illicit drugs during a community-wide treatment-as-prevention initiative. Clinical Infectious Diseases, 62(5), 640–647. https://doi.org/10.1093/cid/civ929
26.
MugaveroM-J., AmicoK. R., HornT., & ThompsonM. A. (2013). The state of engagement in HIV care in the United States: From cascade to continuum to control. Clinical Infectious Diseases, 57(8), 1164–1171. https://doi.org/10.1093/cid/cit420
27.
RichardsonL. A., KerrT. H., DobrerS., PuskasC. M., GuillemiS. A., MontanerJ. S., WoodE., & MilloyM-J. (2015). Socioeconomic marginalization and plasma HIV-1 RNA nondetectability among individuals who use illicit drugs in a Canadian setting. AIDS, 29(18), 2487–2495. https://doi.org/10.1097/QAD.0000000000000853
28.
SpringerS. A., ChenS., & AlticeF. L. (2010). Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: The impact of buprenorphine treatment. Journal of Urban Health, 87(4), 592–602. https://doi.org/10.1007/s11524-010-9438-4
29.
SpringerS. A., PesantiE., HodgesJ., MacuraT., DorosG., & AlticeF. L. (2004). Effectiveness of antiretroviral therapy among HIV-infected prisoners: Reincarceration and the lack of sustained benefit after release to the community. Clinical Infectious Diseases, 38(12), 1754–1760. https://doi.org/10.1086/421392
30.
TiL., MilloyM-J., ShannonK., SimoA., HoggR. S., GuillemiS., MontanerJ., KerrT., & WoodE. (2014). Suboptimal plasma HIV-1 RNA suppression and adherence among sex workers who use illicit drugs in a Canadian setting: An observational cohort study. Sexually Transmitted Infections, 90(5), 418–422. https://doi.org/10.1136/sextrans-2013-051408
WestergaardR. P., KirkG. D., RichessonD. R., GalaiN., & MehtaS. H. (2011). Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clinical Infectious Diseases, 53(7), 725–731. https://doi.org/10.1093/cid/cir491
33.
WoodE., HoggR. S., LimaV. D., KerrT., YipB., MarshallB. D., & MontanerJ. S. (2008). Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA, 300(5), 550–554. https://doi.org/10.1001/jama.300.5.550
34.
WoodE., MilloyM-J., & MontanerJ. S. (2012). HIV treatment as prevention among injection drug users. Current Opinion in HIV and AIDS, 7(2), 151–156. https://doi.org/10.1097/COH.0b013e32834f9927
35.
WoodE., MontanerJ. S., YipB., TyndallM. W., SchechterM. T., O'ShaughnessyM. V., & HoggR. S. (2003). Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. Canadian Medical Association Journal, 169(7), 656–661.
